N4-acylcytosine nucleosides for treatment of viral infections

Abstract

The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N.sup.4-acyl-2′,3′-dideoxy-5-fluorocytidine or N.sup.4-acyl-2′,3′-didehyd-ro-2′,3′-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.

1 - 17 . (canceled) 
     
     
         18 . A compound of formula (I): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein 
         i) X is O, S, NR 5 , CH 2 , CHF or CF 2 ; 
         ii) Y is CH 2 , CHF or CF 2 ; 
         iii) R 1  is chosen from hydrogen, halogen, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cycloalkyl, CN, CF 3 , N 3 , NO 2 , aryl, heteroaryl and acyl; 
         iv) R 2  is chosen from alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, heteroaryl, and C 6 H 4 R 6  where R 6  is chosen from halogen, CN, CF 3 , N 3 , NO 2 , alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, and aryl; 
         v) R 3  and R 3′  are chosen independently from H, halogen, CN, CF 3 , N 3 , NO 2 , alkyl, alkenyl, and alkynyl; and 
         vi) R 4  is H, phosphate, carbonyl substituted with alkyl, alkenyl, alkynyl, aryl, or other pharmaceutically acceptable leaving group, which, when administered in vivo, is capable of providing a compound wherein R 3  and R 3′  are H or phosphate, sulfonate ester, a lipid, an amino acid, a peptide, or cholesterol. 
         vii) R 5  is H, acyl, alkyl, alkenyl, alkynyl, or cycloalkyl. 
       
     
     
         19 . A pharmaceutical composition that includes an effective HIV or HBV treatment amount of a compound of  claim 18  in a pharmaceutically acceptable carrier or diluent. 
     
     
         20 . A method for the treatment of a host infected with HIV that includes administering an effective amount of a compound of  claim 18  in a pharmaceutically acceptable carrier. 
     
     
         21 . A method for the treatment of a host infected with HBV that includes administering an effective amount of a compound of  claim 18  in a pharmaceutically acceptable carrier. 
     
     
         22 . A method for the treatment of a host infected with HIV that includes administering an effective amount of a compound of  claim 18  in a pharmaceutically acceptable carrier in combination with another anti-HIV agent. 
     
     
         23 . A method for the treatment of a host infected with HBV that includes administering an effective amount of a compound of  claim 18  in a pharmaceutically acceptable carrier in combination with another anti-HBV agent. 
     
     
         24 . A compound of  claim 18  for use in the treatment of host infected with HIV. 
     
     
         25 . A compound of  claim 18  for use in the treatment of a host infected with HBV infection.